How COVID-19 changed Canada’s biotech sector

AbCellera's leadership team in a company lab

Canada’s biotech sector has been exploding, with good reason given the events of the last year.

“Innovation and biotechnology was the star of the day.”

The sector has become so significant that it also received a spotlight in the recent federal budget. According to Andrew Casey, President and CEO of BIOTECanada, “innovation and biotechnology was the star of the day.”

Casey joins on the podcast today (recorded right after the budget dropped), along with Anne Woods, managing director of the Life Science and Healthcare practice at Silicon Valley Bank. The two provide an overview of Canada’s biotech landscape, what changed with COVID-19, and the potential impact of federal budget commitments on the sector.

The BetaKit podcast is brought to you by cloud-based accounting software provider Xero.
Learn more about the customized Xero features built specifically for Canadian small businesses.

Subscribe via: RSS, iTunes, Spotify Stitcher, Google Play

Black Swan is a BetaKit podcast. Hosted by Douglas Soltys & Rob Kenedi. Edited by Kattie Laur. Sponsored by Xero. Produced with support from TWG.

0 replies on “How COVID-19 changed Canada’s biotech sector”